A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid to Sanofi in line with its CLA ...
Novavax (NASDAQ:NVAX) has received regulatory approval in Japan for its COVID-19 vaccine, Nuvaxovid, which has resulted in a milestone payment from Takeda (NYSE:TAK) (OTCPK:TKPHF), the company said on ...
There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...
Sept 15 (Reuters) - U.S. drug developer Novavax Inc (NVAX.O), opens new tab said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an ...
This year’s updated COVID-19 vaccines have been approved by the U.S. Food and Drug Administration for adults 65 and older and younger people with certain medical conditions that put them at a higher ...
Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback